Literature DB >> 2227413

Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids.

H S Olsen1, A W Cochrane, P J Dillon, C M Nalin, C A Rosen.   

Abstract

Interaction of the human immunodeficiency virus type 1 (HIV-1) Rev protein with a structured region within env mRNA (termed RRE) mediates the export of virus structural mRNAs from the nucleus to the cytoplasm. We show that the region encompassing the basic stretch of amino acids is essential for the ability of Rev to bind to RRE RNA and function in vivo. By use of a functional truncated Rev protein in conjunction with authentic Rev, effects on gel mobilities of the Rev-RRE RNA complex attributable to multimerization of Rev protein were observed. Rev proteins, unable to multimerize, failed to bind RRE RNA. Identification of Rev mutants capable of forming multimers, but unable to bind RRE RNA, suggests that the multimerization and RNA-binding domains can be distinguished and that multimerization is likely a prerequisite for formation of the RRE RNA-binding site. A mutant Rev protein, shown previously to function as a trans-dominant inhibitor of Rev function, bound to RRE RNA as a multimer to a similar extent as wild-type Rev. This observation is consistent with the hypothesis that regulation of HIV gene expression by Rev involves the interaction with cellular factors and that the trans-dominant Rev is probably defective in this function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2227413     DOI: 10.1101/gad.4.8.1357

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  87 in total

1.  Point mutations in the avian sarcoma/leukosis virus 3' untranslated region result in a packaging defect.

Authors:  J M Aschoff; D Foster; J M Coffin
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Polyvalent Rev decoys act as artificial Rev-responsive elements.

Authors:  T L Symensma; S Baskerville; A Yan; A D Ellington
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Requirements for mouse mammary tumor virus Rem signal peptide processing and function.

Authors:  Hyewon Byun; Nimita Halani; Yongqiang Gou; Andrea K Nash; Mary M Lozano; Jaquelin P Dudley
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

4.  Identification of a domain in human immunodeficiency virus type 1 rev that is required for functional activity and modulates association with subnuclear compartments containing splicing factor SC35.

Authors:  D M D'Agostino; T Ferro; L Zotti; F Meggio; L A Pinna; L Chieco-Bianchi; V Ciminale
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 5.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

6.  Posttranscriptional regulation by the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex proteins through a heterologous RNA binding site.

Authors:  D McDonald; T J Hope; T G Parslow
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Structural and functional analysis of the visna virus Rev-response element.

Authors:  L S Tiley; B R Cullen
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

8.  A novel function for Sam68: enhancement of HIV-1 RNA 3' end processing.

Authors:  Meredith McLaren; Kengo Asai; Alan Cochrane
Journal:  RNA       Date:  2004-07       Impact factor: 4.942

9.  Inhibition of human immunodeficiency virus type 1 Rev function by a Rev mutant which interferes with nuclear/nucleolar localization of Rev.

Authors:  S Kubota; R Furuta; M Maki; M Hatanaka
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes.

Authors:  T J Hope; N P Klein; M E Elder; T G Parslow
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.